Articles from Outcome Capital, LLC

Outcome Capital, LLC, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced the launch of its Healthcare Services Practice, expanding the firm’s strategic and transactional advisory capabilities to meet the needs of companies operating across the rapidly evolving healthcare services sector.

Outcome Capital, LLC, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced that Paul Ryb has been appointed Managing Director and will lead the firm’s dedicated ophthalmology practice, providing strategic guidance, transactional support, and advisory services to clients in the sector. As a highly experienced transaction expert, a leading visually impaired patient advocate, and an ophthalmic venture specialist, Paul has been on a unique and inspiring journey, demonstrating how to “live and succeed with sight-loss”, while supporting, advising and financing ophthalmic innovation across the drug, device, and technology markets for the last 15 years. With vision impairment impacting over 2.2 billion people globally and ranking as a leading cause of disability, the ophthalmology sector urgently requires innovation.

Outcome Capital, LLC, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced that ZIEN Medical Technologies (“ZIEN”), a medical device contract design and manufacturing organization, has entered into a partnership with Averra Holdings, LLC, (“Averra”), a provider of specialized packaging solutions with a focus on the medical device industry and a portfolio company of Banner Capital.

Outcome Capital, LLC, a highly specialized life sciences and healthcare advisory and investment banking firm, congratulates RealizedCare on the success of their company, and acquisition by XRHealth. Outcome Capital served as the exclusive strategic and financial advisor to RealizedCare.

Outcome Capital, LLC, a highly specialized life sciences and healthcare advisory and investment banking firm, which advised Elios Vision, Inc. over several years, developer of minimally invasive glaucoma surgery (MIGS) procedure using an excimer laser, congratulates ELIOS in the success of their company, ultimately culminating in the acquisition by Bausch + Lomb Corporation (NYSE/TSX: BLCO). Over several years, Outcome has played a critical role in the inception, growth and success of ELIOS Vision. Leveraging Outcome Capital’s expertise in corporate strategy, financing, and transaction execution, the firm helped position ELIOS Vision as a key innovator in the $2.5 billion glaucoma treatment market.

Outcome Capital, LLC, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced that Charles Simmons, J.D. has been appointed to the role of Managing Director in its Boston office. The firm continues to expand its Life Sciences and Healthcare practices deploying its unique market-aligned, strategy-driven platform, providing mergers and acquisitions, partnerships, and strategic advisory services.